Original Articles:

• Assessing the Uptake of the Lung Cancer Core Outcome Set: A Cross-Sectional Analysis
• Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK–Positive NSCLC
• Rearranged During Transfection Rearrangement Detection by Fluorescence In Situ Hybridization Compared With Other Techniques in NSCLC
• High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab
• Antibiotic Use and Survival in Patients With Late-Stage NSCLC Treated With Chemoimmunotherapy
• Multisite Randomized Controlled Trial of CareSTEPS: A Supportive Care Intervention for the Family Caregivers of Patients With Advanced Lung Cancer
• Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
• S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
• CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC
• Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18
• Individualized Cell-Free DNA Monitoring With Chromosomal Junctions for Mesothelioma

Brief Reports

• Identifying Novel Germline Mutations and Copy Number Variations in Patients With SCLC
• Developing a Conceptual Framework for a Person-Centered Approach to Improving Adherence and Outcomes in Lung Cancer Screening: The Engaged Approach to Lung Cancer Screening: A Brief Report
• Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief Report
• Brief Report of a New Anatomical Region at Risk in Thoracic Radiotherapy: From Discovery to Implementation
• Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC

Case Reports

• Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports
• Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report
• Entrectinib-Induced Myocarditis and Acute Heart Failure Responding to Steroid Treatment: A Case Report
• First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report

Review Article

• Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications

JTO Clinical and Research Reports is the official open access journal of the International Association for the Study of Lung Cancer. It aims to complement the Journal of Thoracic Oncology by offering authors a gold open access publication option and publishing the following article types in particular:

• Phase I trials
• Well performed single-arm phase II trials
• Subset analyses of published trials
• Impactful retrospective Studies
• Database analysis
• Large institutional series
• High-quality case reports
• Region-specific clinical trials
• Subspecialty thoracic oncology studies
• Selected high-quality meeting reports

As an open access journal with no subscription charges, JTO CRR requires authors to pay a fee to cover the costs associated with publication. This ensures your article will be immediately and permanently free to access by everyone.